PharmTech News

Articles

The companies will integrate Welldoc’s digital insulin management solution, BlueStar, into Eli Lilly’s connected insulin solutions.

Eli Lilly and Welldoc to Collaborate on New Digital Insulin Management Solution

The companies have expanded their existing partnership to include 40 Million Doses of COVID-19 vaccine for South Korea.

Novavax Expands COVID-19 Collaboration and License Agreement with SK Bioscience 

The foundation will provide funding support for the discovery and development of a single-administration, in-vivo gene therapy to cure sickle cell disease, a hereditary blood disease.

Novartis and the Bill & Melinda Gates Foundation Team Up to Develop Gene Therapy for Sickle Cell Disease

4D pharma has signed a clinical trial collaboration and supply agreement with Merck and Pfizer for Bavencio (avelumab).

4D pharma Signs Clinical Trial Collaboration and Supply Agreement with Merck and Pfizer

Exscientia has formed a partnership with the ARUK-ODDI for the development of medicines targeting neuroinflammation to treat Alzheimer’s disease.

Exscientia Partners with University of Oxford on Alzheimer’s Treatments

The cell therapy will be manufactured for each individual patient at BMS’ immunotherapy manufacturing facility in Bothell, WA, and will be launched across a network of treatment centers. 

FDA Approves Bristol Myers Squibb’s CAR T Cell Therapy Lymphoma Treatment

The companies will build capacity in Germany that will be ready in 2022 and are exploring options for increasing volume in 2021.

AstraZeneca and IDT Biologika Plan Vaccine Capacity Expansion 

Through the agreement, AbbVie will use Caribou’s next-generation Cas12a CRISPR hybrid RNA–DNA genome editing and cell therapy technologies to develop two new CAR-T cell therapies.

AbbVie to Collaborate with Caribou Biosciences on CAR-T Cell Therapeutics

The CGMP manufacturing agreement will expand production of lenzilumab, a candidate for COVID-19 therapy, to support a potential emergency use authorization filing.

Avid Bioservices Enters Manufacturing Agreement with Humanigen for Lenzilumab

As demand for COVID-19 vaccines increases, Big Pharma offers its manufacturing capacity and expertise.

Big Pharma Takes on Vaccine Production

The vaccine is 66% effective overall in preventing moderate to severe COVID-19 28 days after vaccination.

J&J’s COVID-19 Vaccine Candidate Effective in Preventing Moderate to Severe COVID-19

The vaccine met the primary endpoint with a vaccine efficacy of 89.3% in its Phase III trial in the United Kingdom and a vaccine efficacy of 49% in HIV-positive participants and 60% in HIV-negative participants in a South African Phase IIb trial. 

Novavax Shares Data from UK and South Africa COVID-19 Vaccine Candidate Trials 

Evozyne’s evolution-based protein design technology will be used to research and develop proteins that could be used in the next generation of gene therapies.

Takeda and Evozyne Enter into Gene Therapy Collaboration 

The company is discontinuing the development of its SARS-CoV-2/COVID-19 vaccine candidates, V590 and V591, to focus on advancing its two SARS-CoV-2/COVID-19 therapeutic candidates, MK-4482 and MK-7110. 

Merck Halts Development of its COVID-19 Vaccine Candidates

The drug offers immediate post-exposure protection against the virus and will serve as a counterpart to the vaccine during its early phases.

Grifols Initiates Trial for New COVID-19 Drug

Through the acquisition, Thermo Fisher will have access to Mesa’s PCR-based rapid point-of-care testing platform for detecting infectious diseases.

Thermo Fisher to Acquire Mesa Biotech for $450 Million

This new agreement covers 1.25 million additional doses of the antibody cocktail containing casirivimab and imdevimab for the treatment of COVID-19.

US Government to Purchase Additional Doses of Regeneron’s COVID-19 Antibody Cocktail

The collaboration will focus on up to three types of lung and gastrointestinal cancers.

Boehringer Ingelheim and Enara Bio Partner on Cancer Immunotherapies

The first four investments of the new program will support clinical-stage biotechnology companies while new investments will include companies focused on oncology, rare disease, and inflammation and immunology.

Pfizer Invests $120 Million in Biotechnology Innovation

Bayer will support the development and supply of CureVac’s COVID-19 vaccine candidate, CVnCoV.

Bio/Pharma News